The Evidence for Hypoperfusion As a Factor in Multiple Sclerosis Lesion Development

Overview

Journal Mult Scler Int

Publisher Wiley

Date 2013 May 22

PMID 23691321

Citations 15

Authors

Bernhard H J Juurlink

Affiliations

Soon will be listed here.

Abstract

The evidence that hypoxia is a precipitating factor in causing early MS lesions includes increased protein levels of hypoxia-inducible factor-1 α ; presence of the D-110 hypoxia-inducible protein; increased expression of hypoxia-inducible genes in lesions as well as in adjacent normal-appearing white matter (NAWM); loss of myelin-associated glycoprotein in myelin of early MS lesions; a 50% reduction of blood flow through NAWM with areas of lowest blood flow having the greatest probability of lesion development. Why MS-like lesions develop following hypoxemic insults in some individuals but not in others is likely dependent upon the presence of immune predisposing factors that are governed genetically. Hypoperfusion may be due to decreased arterial supply, restricted venous return, or a combination of these. There are clinical trials ongoing or planned to treat chronic cerebrospinal venous insufficiency (CCSVI) through angioplasty. I suggest that it is important that clinical trials addressing vascular issues in MS should examine how the vascular intervention affects white matter perfusion and determine whether the extent of perfusion recovery and maintenance of this recovery is related to functional recovery and maintenance of functional recovery. Consideration should also be given to the possibility of arterial problems playing a role in hypoperfusion in some MS patients.

Citing Articles

Cytokines, Vascular Endothelial Growth Factors, and PlGF in Autoimmunity: Insights From Rheumatoid Arthritis to Multiple Sclerosis.

Lee Y, Lee S, Kim W Immune Netw. 2024; 24(1):e10.

PMID: 38455464 PMC: 10917575. DOI: 10.4110/in.2024.24.e10.

Microglia/macrophage polarization regulates spontaneous remyelination in intermittent cuprizone model of demyelination.

Zarini D, Pasbakhsh P, Mojaverrostami S, Amirizadeh S, Hashemi M, Shabani M Biochem Biophys Rep. 2024; 37:101630.

PMID: 38234370 PMC: 10793082. DOI: 10.1016/j.bbrep.2023.101630.

Changes in brain perfusion with training-related visuomotor improvement in MS.

Patitucci E, Lipp I, Stickland R, Wise R, Tomassini V Front Mol Neurosci. 2023; 16:1270393.

PMID: 38025268 PMC: 10665528. DOI: 10.3389/fnmol.2023.1270393.

Oxygen treatment reduces neurological deficits and demyelination in two animal models of multiple sclerosis.

Amatruda M, Harris K, Matis A, Davies A, McElroy D, Clark M Neuropathol Appl Neurobiol. 2022; 49(1):e12868.

PMID: 36520661 PMC: 10107096. DOI: 10.1111/nan.12868.

Cerebrovascular Reactivity and Neurovascular Coupling in Multiple Sclerosis-A Systematic Review.

Vestergaard M, Frederiksen J, Larsson H, Cramer S Front Neurol. 2022; 13:912828.

PMID: 35720104 PMC: 9198441. DOI: 10.3389/fneur.2022.912828.

References

Reimer M, McQueen J, Searcy L, Scullion G, Zonta B, Desmazieres A . Rapid disruption of axon-glial integrity in response to mild cerebral hypoperfusion. J Neurosci. 2011; 31(49):18185-94. PMC: 4337974. DOI: 10.1523/JNEUROSCI.4936-11.2011. View

Lassmann H, Reindl M, Rauschka H, Berger J, Aboul-Enein F, Berger T . A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain. 2003; 126(Pt 6):1347-57. DOI: 10.1093/brain/awg127. View

Gonzalez-Andrade F, Alcaraz-Alvarez J . Disease-modifying therapies in relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2010; 6:365-73. PMC: 2938285. DOI: 10.2147/ndt.s11079. View

Juurlink B . The multiple sclerosis lesion: initiated by a localized hypoperfusion in a central nervous system where mechanisms allowing leukocyte infiltration are readily upregulated?. Med Hypotheses. 1998; 51(4):299-303. DOI: 10.1016/s0306-9877(98)90052-4. View

Ge Y, Law M, Johnson G, Herbert J, Babb J, Mannon L . Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am J Neuroradiol. 2005; 26(6):1539-47. PMC: 8149080. View

Taylor C . Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol. 2008; 586(17):4055-9. PMC: 2652186. DOI: 10.1113/jphysiol.2008.157669. View

Zamboni P, Galeotti R, Menegatti E, Malagoni A, Tacconi G, DallAra S . Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008; 80(4):392-9. PMC: 2647682. DOI: 10.1136/jnnp.2008.157164. View

Haacke E . Chronic cerebral spinal venous insufficiency in multiple sclerosis. Expert Rev Neurother. 2010; 11(1):5-9. DOI: 10.1586/ern.10.174. View

La Mantia L, Vacchi L, Rovaris M, Di Pietrantonj C, Ebers G, Fredrikson S . Interferon β for secondary progressive multiple sclerosis: a systematic review. J Neurol Neurosurg Psychiatry. 2012; 84(4):420-6. DOI: 10.1136/jnnp-2012-303291. View

10.

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H . Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47(6):707-17. DOI: 10.1002/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q. View

11.

Graumann U, Reynolds R, Steck A, Schaeren-Wiemers N . Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 2003; 13(4):554-73. PMC: 8096038. DOI: 10.1111/j.1750-3639.2003.tb00485.x. View

12.

Farooqi N, Gran B, Constantinescu C . Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?. J Neurochem. 2010; 115(4):829-44. DOI: 10.1111/j.1471-4159.2010.06982.x. View

13.

Utriainen D, Feng W, Elias S, Latif Z, Hubbard D, Haacke E . Using magnetic resonance imaging as a means to study chronic cerebral spinal venous insufficiency in multiple sclerosis patients. Tech Vasc Interv Radiol. 2012; 15(2):101-12. DOI: 10.1053/j.tvir.2012.02.003. View

14.

Cunnea P, Mhaille A, McQuaid S, Farrell M, McMahon J, Fitzgerald U . Expression profiles of endoplasmic reticulum stress-related molecules in demyelinating lesions and multiple sclerosis. Mult Scler. 2011; 17(7):808-18. DOI: 10.1177/1352458511399114. View

15.

Law M, Saindane A, Ge Y, Babb J, Johnson G, Mannon L . Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology. 2004; 231(3):645-52. DOI: 10.1148/radiol.2313030996. View

16.

DHaeseleer M, Cambron M, Vanopdenbosch L, De Keyser J . Vascular aspects of multiple sclerosis. Lancet Neurol. 2011; 10(7):657-66. DOI: 10.1016/S1474-4422(11)70105-3. View

17.

Inglese M, Adhya S, Johnson G, Babb J, Miles L, Jaggi H . Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab. 2007; 28(1):164-71. PMC: 2596621. DOI: 10.1038/sj.jcbfm.9600504. View

18.

Adhya S, Johnson G, Herbert J, Jaggi H, Babb J, Grossman R . Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage. 2006; 33(4):1029-35. PMC: 1752216. DOI: 10.1016/j.neuroimage.2006.08.008. View

19.

Saindane A, Law M, Ge Y, Johnson G, Babb J, Grossman R . Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum: support for primary hypoperfusion in multiple sclerosis. AJNR Am J Neuroradiol. 2007; 28(4):767-72. PMC: 7977353. View

20.

Schmedtje Jr J, Ji Y, Liu W, DuBois R, Runge M . Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem. 1997; 272(1):601-8. DOI: 10.1074/jbc.272.1.601. View